DAFNA Capital Management’s Indaptus Therapeutics INDP Stock Holding History

DAFNA Capital Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-186	Closed	-$1.8M	–	90
2019 Q2	$1.8M	Buy	186 +16	+9%	+$202K	0.68%	42
2019 Q1	$2.8M	Sell	170 -37	-18%	-$648K	1.21%	29
2018 Q4	$3.49M	Sell	207 -33	-14%	-$450K	1.74%	20
2018 Q3	$3.03M	Sell	240 -14	-6%	-$133K	1.25%	29
2018 Q2	$2.5M	Buy	+254	New	+$2.82M	1.17%	27
2016 Q3	–	Sell	-53	Closed	-$549K	–	89
2016 Q2	$549K	Hold	53	–	–	0.44%	57
2016 Q1	$491K	Hold	53	–	–	0.42%	64
2015 Q4	$639K	Sell	53 -7	-12%	-$89.9K	0.57%	46
2015 Q3	$756K	Buy	+60	New	+$788K	0.75%	37

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

DAFNA Capital Management's INDP Position: Q3 2019 in Review

DAFNA Capital Management sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 186 shares — an estimated $1.8M sold.

DAFNA Capital Management first reported a position in INDP in Q3 2015 and held it in 9 quarters. The position peaked at $3.49M in Q4 2018. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

DAFNA Capital Management reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
DAFNA Capital Management sold 186 Indaptus Therapeutics shares in Q3 2019, an estimated $1.8M.
DAFNA Capital Management first reported a position in Indaptus Therapeutics in Q3 2015 and held it in 9 quarters.
DAFNA Capital Management's Indaptus Therapeutics position peaked at $3.49M in Q4 2018.
33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.